Related Experiment Video

Updated: Jun 5, 2025

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.0K

Potential therapeutic strategies for colitis and colon cancer: bidirectional targeting STING pathway

Jiaorong Qu1, Yajie Cai2, Fanghong Li2

  • 1School of Life Sciences, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Beijing, 100029, China.

Ebiomedicine
|December 7, 2024
PubMed

Insights

Targeting the cyclic-GMP-AMP synthase (cGAS)-stimulator of interferon gene (STING) pathway offers dual therapeutic potential for colitis and colon cancer. Modulating STING activity presents a promising strategy for treating these conditions.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • The cyclic-GMP-AMP synthase (cGAS)-stimulator of interferon gene (STING) pathway plays a critical role in innate immunity.
  • Dysregulation of the STING pathway is implicated in the pathogenesis of colitis and colon cancer.

Purpose of the Study:

  • To provide a comprehensive review of STING agonists and inhibitors for colitis and colon cancer.
  • To explore the molecular mechanisms underlying STING pathway modulation in these diseases.
  • To identify novel druggable targets for STING-based therapies.

Main Methods:

  • Systematic literature review of STING inhibitors and agonists.
  • Analysis of molecular mechanisms of STING pathway regulation.
  • Evaluation of STING oligomerization, degradation, and phase separation.

Main Results:

  • STING inhibition may mitigate colitis progression.
  • STING activation can enhance anti-tumor immunity in colon cancer.
  • Emerging insights into STING self-regulation reveal potential therapeutic targets.

Conclusions:

  • Targeting the STING pathway holds significant clinical translational potential for colitis and colon cancer.
  • Development of specific STING agonists and inhibitors is a promising therapeutic strategy.
  • Further validation of novel STING-targeting agents is warranted.
Keywords:
ColitisColon cancerSTINGSTING agonistsSTING inhibitors

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.4K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

818

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
112
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
118
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142